الصفحة الرئيسية>>Signaling Pathways>> Tyrosine Kinase>> VEGFR>>VEGFR Tyrosine Kinase Inhibitor II

VEGFR Tyrosine Kinase Inhibitor II (Synonyms: Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor II)

رقم الكتالوجGC16062

مثبط VEGFR Tyrosine Kinase II (المركب 3) هو مثبط قوي لتكوين الأوعية الدموية مع IC50s 0.02 و 0.18 و 0.24 7.3 و 7 μ ؛ M لـ KDR و Flt-1 و c-Kit و EGF-R و c-Src ، على التوالي .

Products are for research use only. Not for human use. We do not sell to patients.

VEGFR Tyrosine Kinase Inhibitor II التركيب الكيميائي

Cas No.: 269390-69-4

الحجم السعر المخزون الكميّة
1mg
87٫00
متوفر
5mg
253٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

VEGFR tyrosine kinase inhibitor II is a pyridinyl-anthranilamide compound that inhibits the kinase activities of VEGFR2 (KDR), VEGFR1 (FLT1), and c-Kit (IC50s = 20, 180, and 240 nM, respectively).1 It displays minimal activity against c-Src and EGFR (IC50s = 7 and 7.3 µM, respectively) and is inactive against Cdk1, c-Met, IGF-1R, and PKA (IC50s > 10 µM).1 VEGFR tyrosine kinase inhibitor II has been investigated for its potential to inhibit tumor induced angiogenesis.[1]

Reference:
[1] Furet, P., Bold, G., Hofmann, F., et al. Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching. Bioorganic & Medicinal Chemistry Letters 13(18), 2967-2971 (2003).

مراجعات

Review for VEGFR Tyrosine Kinase Inhibitor II

Average Rating: 5 ★★★★★ (Based on Reviews and 19 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for VEGFR Tyrosine Kinase Inhibitor II

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.